• Figure 1.

    Summary of the drugs that target the complement cascade in glomerular disease

  • 1.

    Rodriguez E , et al.. Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome? Clin Kidney J 2017; 10:320322. doi: 10.1093/ckj/sfx024

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Skoczynska M , et al.. Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: Case report and systematic review of the literature. Lupus 2020; 29:631639. doi: 10.1177/0961203320917460

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Nakamura H , et al.. Atypical hemolytic uremic syndrome associated with complement factor H mutation and IgA nephropathy: A case report successfully treated with eculizumab. Nephron 2018; 138:324327. doi: 10.1159/000485194

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Palomo M , et al.. Complement activation and thrombotic microangiopathies. Clin J Am Soc Nephrol 2019; 14:17191732. doi: 10.2215/CJN.05830519

  • 5.

    Ariceta G , et al.. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int [published online ahead of print December 8, 2020]. doi: 10.1016/j.kint.2020.10.046; https://www.kidney-international.org/article/S0085-2538(20)31418-6/fulltext

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Jayne DRW , et al.. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol 2017; 28:27562767. doi: 10.1681/ASN.2016111179

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Jayne DRW , et al.. ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 2021; 384:599609. doi: 10.1056/NEJMoa2023386

  • 8.

    Merkel PA , et al.. Evaluation of the safety and efficacy of avacopan, a C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated concomitantly with rituximab or cyclophosphamide/azathioprine: Protocol for a randomized, double-blind, active-controlled, phase 3 trial. JMIR Res Protoc 2020; 9:e16664. doi: 10.2196/16664

    • PubMed
    • Search Google Scholar
    • Export Citation

Complement Inhibition in Kidney Disease. What’s on the Horizon?

Maria Jose Soler Maria Jose Soler, MD, PhD, FERA, is a nephrologist, and Natalia Ramos, MD, PhD, is a nephrology attendant with the Nephrology Department, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Research, Barcelona, Spain.

Search for other papers by Maria Jose Soler in
Current site
Google Scholar
PubMed
Close
and
Natalia Ramos Maria Jose Soler, MD, PhD, FERA, is a nephrologist, and Natalia Ramos, MD, PhD, is a nephrology attendant with the Nephrology Department, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Research, Barcelona, Spain.

Search for other papers by Natalia Ramos in
Current site
Google Scholar
PubMed
Close
Restricted access
Save